amiokordin 200 mg
krka, d.d., novo mesto, slovinsko - amiodarón - 13 - antiarrythmica
rivodaron 200
pro.med.cs praha a.s., Česká republika - amiodarón - 13 - antiarrythmica
ribas 20 mg filmom obalené tablety
belupo lijekovi i kozmetika d.d., chorvátska republika - rivaroxabán - 16 - anticoagulantia (fibrinolytica, antifibrinol.)
ribas 15 mg filmom obalené tablety
belupo lijekovi i kozmetika d.d., chorvátska republika - rivaroxabán - 16 - anticoagulantia (fibrinolytica, antifibrinol.)
isoptin 40 mg
viatris healthcare limited, Írsko - verapamil - 13 - antiarrythmica
isoptin 80 mg
viatris healthcare limited, Írsko - verapamil - 13 - antiarrythmica
isoptin sr 240 mg
viatris healthcare limited, Írsko - verapamil - 13 - antiarrythmica
isoptin ichs retard
viatris healthcare limited, Írsko - verapamil - 13 - antiarrythmica
betmiga
astellas pharma europe b.v. - mirabegron - močový mechúr, hyperaktívny - urologika - symptomatická liečba naliehavosti. zvýšená micturition frekvencia a / alebo naliehavosti inkontinencie ako sa môžu vyskytnúť u dospelých pacientov s hyperaktívneho močového-mechúra syndróm.
cabometyx
ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antineoplastické činidlá - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.